ECSP099441A - Nuevos intermediarios y procesos útiles en la preparación de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona - Google Patents

Nuevos intermediarios y procesos útiles en la preparación de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona

Info

Publication number
ECSP099441A
ECSP099441A EC2009009441A ECSP099441A ECSP099441A EC SP099441 A ECSP099441 A EC SP099441A EC 2009009441 A EC2009009441 A EC 2009009441A EC SP099441 A ECSP099441 A EC SP099441A EC SP099441 A ECSP099441 A EC SP099441A
Authority
EC
Ecuador
Prior art keywords
piridin
chlorophenyl
pyridin
bis
preparation
Prior art date
Application number
EC2009009441A
Other languages
English (en)
Inventor
Michael Edward Kobierski
Michael E Kopach
Pingyun Chen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP099441A publication Critical patent/ECSP099441A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

La presente invención se refiere a nuevos compuestos, benzoato de (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-il-vinil)piridin-3-il]metanona, y toluato de (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-il-vinil)piridin-3-il]metanono, los cuales son intermediarios útiles para la preparación del compuesto de Fórmula I:(I)La presente invención además se refiere a nuevos procesos para preparar un compuesto cristalino, el cual es {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1H-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona, Forma IV.
EC2009009441A 2006-12-20 2009-06-17 Nuevos intermediarios y procesos útiles en la preparación de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona ECSP099441A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87085106P 2006-12-20 2006-12-20

Publications (1)

Publication Number Publication Date
ECSP099441A true ECSP099441A (es) 2009-07-31

Family

ID=39273082

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009441A ECSP099441A (es) 2006-12-20 2009-06-17 Nuevos intermediarios y procesos útiles en la preparación de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona

Country Status (22)

Country Link
US (4) US8772496B2 (es)
EP (1) EP2121610B1 (es)
JP (1) JP5443168B2 (es)
KR (1) KR20090081028A (es)
CN (1) CN101568523A (es)
AU (1) AU2007337255A1 (es)
BR (1) BRPI0721069A2 (es)
CA (1) CA2671770C (es)
DK (1) DK2121610T3 (es)
EA (1) EA200970604A1 (es)
EC (1) ECSP099441A (es)
ES (1) ES2471990T3 (es)
HR (1) HRP20140613T1 (es)
IL (1) IL198775B (es)
MX (1) MX2009006636A (es)
NO (1) NO20092370L (es)
PL (1) PL2121610T3 (es)
PT (1) PT2121610E (es)
RS (1) RS53386B (es)
SI (1) SI2121610T1 (es)
WO (1) WO2008079600A1 (es)
ZA (1) ZA200903578B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2121610E (pt) * 2006-12-20 2014-06-25 Lilly Co Eli Novos intermediários e processo útil para a preparação da {2-[1-(3,5-bis-trifluorometil-benzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona
US10098859B2 (en) 2012-09-05 2018-10-16 Amri Ssci, Llc Cocrystals of p-coumaric acid
BR112017018620A2 (pt) 2015-03-04 2018-04-17 Vanda Pharmaceuticals Inc. método de administração de tradipitanto, e, tradipitanto.
WO2017031215A1 (en) * 2015-08-17 2017-02-23 Eli Lilly And Company Process development of a pyridine-containing nk-1 receptor antagonist
CN111093671A (zh) 2017-09-13 2020-05-01 万达制药公司 以托吡坦对特应性皮炎的改进治疗
CA3081582A1 (en) 2017-11-17 2019-05-23 Vanda Pharmaceuticals Inc. Method of treatment of gastrointestinal diseases with tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
EP3890735A1 (en) 2018-12-03 2021-10-13 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US20230145932A1 (en) * 2020-03-26 2023-05-11 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2483159C (en) 2002-04-26 2010-08-10 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
ES2340772T3 (es) * 2003-10-24 2010-06-09 Eli Lilly And Company Nuevas formas cristalinas (2-(1-(3,5-bis-trifluorometilbencil)-5-piridin-4-il-1h-(1,2,3)triazol-4-il)-piridin-3-il)-(2-clorofenil)-metadona.
WO2006083711A1 (en) * 2005-02-01 2006-08-10 Eli Lilly And Company Tachykinin receptor antagonists
PT2121610E (pt) * 2006-12-20 2014-06-25 Lilly Co Eli Novos intermediários e processo útil para a preparação da {2-[1-(3,5-bis-trifluorometil-benzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona

Also Published As

Publication number Publication date
IL198775A0 (en) 2010-02-17
CA2671770A1 (en) 2008-07-03
WO2008079600A1 (en) 2008-07-03
DK2121610T3 (da) 2014-06-30
US20160060250A1 (en) 2016-03-03
US10035787B2 (en) 2018-07-31
NO20092370L (no) 2009-09-16
RS53386B (en) 2014-10-31
US20100056795A1 (en) 2010-03-04
BRPI0721069A2 (pt) 2014-02-04
CA2671770C (en) 2015-09-15
ES2471990T3 (es) 2014-06-27
AU2007337255A1 (en) 2008-07-03
SI2121610T1 (sl) 2014-08-29
JP2010513546A (ja) 2010-04-30
US20170283394A1 (en) 2017-10-05
EA200970604A1 (ru) 2009-10-30
US9708291B2 (en) 2017-07-18
US20140206877A1 (en) 2014-07-24
MX2009006636A (es) 2009-06-30
PL2121610T3 (pl) 2014-09-30
EP2121610B1 (en) 2014-04-02
ZA200903578B (en) 2010-07-28
IL198775B (en) 2018-08-30
PT2121610E (pt) 2014-06-25
EP2121610A1 (en) 2009-11-25
CN101568523A (zh) 2009-10-28
KR20090081028A (ko) 2009-07-27
JP5443168B2 (ja) 2014-03-19
US8772496B2 (en) 2014-07-08
HRP20140613T1 (hr) 2014-08-15

Similar Documents

Publication Publication Date Title
ECSP099441A (es) Nuevos intermediarios y procesos útiles en la preparación de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona
AR121612A2 (es) Inhibidores de glucosilceramida sintasa
NO20084783L (no) Syntese av acylaminoalkenylenamider nyttige som substans P antagonister
ECSP099818A (es) Procesos para la preparacion de pirazoles
NI201100049A (es) Compuestos orgánicos.
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
PE20091493A1 (es) Inhibidores de quinasa de pirrolopirazina
CR20140301A (es) Derivados de betulina
AR070395A1 (es) Derivados de 4,5-dihidro-oxazol-2-il- amina
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt
PE20131153A1 (es) Inhibidores de la tirosina-quinasa de bruton
WO2009065919A3 (de) Organische verbindungen
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
WO2009065920A3 (de) Verbindungen
MX347562B (es) Derivados fungicidas de 3-fenil[(heterociclilmetoxi)imino]metil}-1 ,2,4-oxadiazol-5(4h)-ona sustituidos en 4.
MY150778A (en) Fused heterocyclic compound
PE20081735A1 (es) Derivados de 1-oxa-3[4,5]decan-2-ona en el tratamiento de trastornos alimenticios
WO2009065922A3 (de) Organische verbindungen
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
MX2011011281A (es) Compuesto de carbinol que tiene un enlazante heterociclico.
MY156233A (en) Disubstituted tetrahydrofuranyl compounds as antagonists of the bradykinin b1 receptor
NZ597916A (en) Benzoquinolizinium salt derivatives as anticancer agents
RS54012B1 (en) UNITS USED FOR CHK1 INHIBITION
WO2009034029A3 (de) 1-substituierte 4 -heterocyclylpiperidine als cgrp antagonisten
MX2009010727A (es) Heterociclos como antagonistas de orexina.